Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Metrics to compare | CRDL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRDLPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.6x | −1.3x | −0.5x | |
PEG Ratio | 1.88 | 0.01 | 0.00 | |
Price/Book | 9.4x | 0.9x | 2.6x | |
Price / LTM Sales | - | 0.6x | 3.2x | |
Upside (Analyst Target) | - | 103.4% | 42.0% | |
Fair Value Upside | Unlock | 1.6% | 6.6% | Unlock |